Affiliation:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Abstract
Lymphoblastic lymphomas (LBL) are the second most common subtype of non-Hodgkin’s lymphomas in children and adolescents, accounting for 25–35 % of all non-Hodgkin’s lymphomas cases. The majority of all lymphoblastic lymphomas (80–85 %) are T-lymphoblastic origin; 15–20 % origins from B-cell precursors, biphenotypic LBL are extremely rare. Currently, the overall and relapse-free survival of children and adolescents with LBL exceeds 80 %, uses of modern therapy programs. However, the survival rates of patients with recurrent or refractory LBL remain low – 10 %. Optimization of therapeutic approaches in LBL follows the path of clarifying clinical, morpho-immunological and molecular biological risk groups, modification of treatment programs using new drugs (including immunotherapy, inhibitors of multifunctional intracellular signaling pathways (NOTCH, PI3K/AKТ/mTOR, JAK/STAT and MAPK), affecting the cell cycle regulation), and also a reduction in immediate and long-term toxicity. This article presents modern approaches to the diagnosis of LBL, staging and choosing of a treatment method.
Publisher
Publishing House ABV Press
Reference41 articles.
1. Raetz E.A., Perkins S.L., Bhojwani D. et al. Gene expression profiling reveals intrinsic differences between T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Pediatr Blood Cancer 2006;47(2):130–40. DOI: 10.1002/pbc.20550
2. Borowitz M.J., Chan J.K., Downing J.R. et al. B-lymphoblastic leukaemia/lymphoma, not otherwise specified (NOS). In: WHO classification of tumours of haematopoietic and lymphoid tissues. Revised. 4th edn. Eds.: S.H. Swerdlow, E. Campo, N.L. Harris et al. Lyon, France: IARC, 2017. Pp. 200–202.
3. Pavlova T.Yu., Valiev T.T. Experience in the treatment of progenitor cells lymphoblastic lymphomas in children and adolescents according to the ALL IC-BFM 2002/2009 protocols. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2023; 22(2, Suppl. 1): 141. (In Russ.).
4. Aleshina O.A., Galtseva I.V., Kotova E.S. et al. Treatment outcomes for acute Tlymphoblastic leukemias/lymphomas: data from the ALL2016 multicenter prospective randomized trial. Onkogematologiya = Oncohematology 2023;18(1):20–30. (In Russ.). DOI: 10.17650/1818834620231812030
5. Chen H., Qin Y., Yang J. et al. Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: a retrospective study from China. Asia Pac J Clin Oncol 2022;18(2):87–95. DOI: 10.1111/ajco.13562